Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies
AbstractRecombinant monoclonal antibodies (mAbs) intended for therapeutic usage are required to be thoroughly characterized, which has promoted an extensive effort towards the understanding of the structures and heterogeneity of this major class of molecules. Batch consistency and comparability are highly relevant to the successful pharmaceutical development of mAbs and related products. Small structural modifications that contribute to molecule variants (or proteoforms) differing in size, charge or hydrophobicity have been identified. These modifications may impact (or not) the stability, pharmacokinetics, and efficacy of mAbs. The presence of the same type of modifications as found in endogenous immunoglobulin G (IgG) can substantially lower the safety risks of mAbs. The knowledge of modifications is also critical to the ranking of critical quality attributes (CQAs) of the drug and define the Quality Target Product Profile (QTPP). This review provides a summary of the current understanding of post-translational and physico-chemical modifications identified in recombinant mAbs and endogenous IgGs at physiological conditions. View Full-Text
Share & Cite This Article
Beck, A.; Liu, H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. Antibodies 2019, 8, 18.
Beck A, Liu H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. Antibodies. 2019; 8(1):18.Chicago/Turabian Style
Beck, Alain; Liu, Hongcheng. 2019. "Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies." Antibodies 8, no. 1: 18.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.